secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001193125-23-171157
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir suspends ATM equity program; terminates prospectus supplement with SVB
------------------------------------------------------------------------------

- Notified SVB Securities on June 21, 2023 to suspend and terminate the ATM prospectus supplement.
- No sales of common stock will be made under the Sales Agreement until a new prospectus supplement or registration statement is filed.
- Sales Agreement dated August 6, 2021 remains in full force and effect except for the terminated supplement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523171157/0001193125-23-171157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523171157/d462085d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-171157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer